健康研究
健康研究
건강연구
HEALTH RESEARCH
2014年
5期
518-519
,共2页
布地奈德%匹多莫德%毛细支气管炎%哮喘
佈地奈德%匹多莫德%毛細支氣管炎%哮喘
포지내덕%필다막덕%모세지기관염%효천
Budesonide%pidotimod%bronchiolitis%asthma
目的:观察布地奈德联合匹多莫德干预毛细支气管炎预防哮喘的临床效果。方法将93例呼吸道合胞病毒感染毛细支气管炎患儿随机分为观察组(47例)和对照组(46例),两组均予抗病毒及对症处理,对照组加匹多莫德口服2月,观察组在对照组基础上加布地奈德经储雾罐吸入,观察比较治疗后3个月患者T细胞亚群变化及2年内哮喘的发生率。结果3个月后观察组较对照组免疫功能显著提高(P<0.01),2年内哮喘的发生率显著降低(χ2=5.23,P<0.05)。结论布地奈德联合匹多莫德干预毛细支气管炎预防哮喘效果显著。
目的:觀察佈地奈德聯閤匹多莫德榦預毛細支氣管炎預防哮喘的臨床效果。方法將93例呼吸道閤胞病毒感染毛細支氣管炎患兒隨機分為觀察組(47例)和對照組(46例),兩組均予抗病毒及對癥處理,對照組加匹多莫德口服2月,觀察組在對照組基礎上加佈地奈德經儲霧罐吸入,觀察比較治療後3箇月患者T細胞亞群變化及2年內哮喘的髮生率。結果3箇月後觀察組較對照組免疫功能顯著提高(P<0.01),2年內哮喘的髮生率顯著降低(χ2=5.23,P<0.05)。結論佈地奈德聯閤匹多莫德榦預毛細支氣管炎預防哮喘效果顯著。
목적:관찰포지내덕연합필다막덕간예모세지기관염예방효천적림상효과。방법장93례호흡도합포병독감염모세지기관염환인수궤분위관찰조(47례)화대조조(46례),량조균여항병독급대증처리,대조조가필다막덕구복2월,관찰조재대조조기출상가포지내덕경저무관흡입,관찰비교치료후3개월환자T세포아군변화급2년내효천적발생솔。결과3개월후관찰조교대조조면역공능현저제고(P<0.01),2년내효천적발생솔현저강저(χ2=5.23,P<0.05)。결론포지내덕연합필다막덕간예모세지기관염예방효천효과현저。
Objective To understand the effect of the medicine of curing bronchiolitis with a combination of Budesonide and Pidotimod in preventing asthma.Method 93 children with respiratory syncytial virus infection bronchiolitis were chosen as the subjects for study and randomly divided into an experimental group (n=47) and a control group (n=46). Both groups were provided with anti-virus and symptomatic treatment.The control group took Pidotimod 0.4/time orally for 2 months.In addition to anti-virus and symptomatic treatment, the experimental group inhaled budesonide by spacer, 100 ug/time, 1 to 2 times per day, for two months.T-cell subsets and the incidence of asthma in the two years were observed and compared.Findings 3 months after treatment, the immune function in the experimental group was found to improve than in the control group ( P <0.01).Two years after treatment, the incidence of asthma was found to decrease significantly in the experimental group (P<0.05).The difference was significant.Conclusion The medicine of curing bronchiolitis with a combination of Budesonide and pidotimod first for preventing asthma has been proved to be effective.